Drug Delivery (Jan 2017)

In vitro and in vivo evaluation of macromolecular prodrug GC-FUA based nanoparticle for hepatocellular carcinoma chemotherapy

  • Can Huang,
  • Na-Mei Li,
  • Pei Gao,
  • Sa Yang,
  • Qian Ning,
  • Wen Huang,
  • Zhi-Ping Li,
  • Peng-Ju Ye,
  • Li Xiang,
  • Dong-Xiu He,
  • Xiang-Wen Tan,
  • Cui-Yun Yu

DOI
https://doi.org/10.1080/10717544.2016.1264499
Journal volume & issue
Vol. 24, no. 1
pp. 459 – 466

Abstract

Read online

A novel type of macromolecular prodrug delivery system is reported in this research. The N-galactosylated-chitosan-5-fluorouracil acetic acid conjugate (GC-FUA) based nanoparticle delivery system was evaluated in vitro and in vivo. Biocompatibility of GC-FUA-NPs was screened by BSA adsorption test and hemolysis activity examination in vitro. Cytotoxicity and cellular uptake study in HepG2 and A549 cells demonstrated that compared to free 5-Fu, the GC-FUA-NPs play great function in killing cancer cells for the cell endocytosis mediated by asialoglycoprotein receptor (ASGPR), which overexpresses on the cell surface. Pharmacokinetics study further illustrated that the drug-loaded nanoparticles has a much longer half-time than free 5-Fu in blood circulation in Sprague–Dawley (SD) rats. Tissue distribution was investigated in Kunming mice, and the result showed that the GC-FUA-NPs have a long circulation effect. The obtained data suggested that GC-FUA-NP is a very promising drug delivery system for efficient treatment of hepatocellular carcinoma.

Keywords